Temporal Relationship Between Serum Neurofilament Light Chain and Radiologic Disease Activity in Patients With Multiple Sclerosis

Serum neurofilament light chain; Radiologic disease; Multiple sclerosis

Detalles Bibliográficos
Autores: Fox, Robert J, Cree, Bruce, de Seze, Jerome, Hartung, Hans-Peter, Jeffery, Douglas, Gold, Ralf, Montalban, Xavier
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2024
País:España
Institución:Departament de Salut de la Generalitat de Catalunya (DS)
Repositorio:Scientia. Dipòsit d'Informació Digital del Departament de Salut
OAI Identifier:oai:scientiasalut.gencat.cat:11351/11386
Acceso en línea:https://hdl.handle.net/11351/11386
Access Level:acceso abierto
Palabra clave:Esclerosi múltiple - Imatgeria per ressonància magnètica
Marcadors bioquímics
Filaments citoplasmàtics
DISEASES::Nervous System Diseases::Autoimmune Diseases of the Nervous System::Demyelinating Autoimmune Diseases, CNS::Multiple Sclerosis
Other subheadings::Other subheadings::Other subheadings::/diagnostic imaging
CHEMICALS AND DRUGS::Macromolecular Substances::Polymers::Biopolymers::Intermediate Filament Proteins::Neurofilament Proteins
CHEMICALS AND DRUGS::Biological Factors::Biomarkers
ENFERMEDADES::enfermedades del sistema nervioso::enfermedades autoinmunitarias del sistema nervioso::enfermedades autoinmunes desmielinizantes del SNC::esclerosis múltiple
Otros calificadores::Otros calificadores::Otros calificadores::/diagnóstico por imagen
COMPUESTOS QUÍMICOS Y DROGAS::sustancias macromoleculares::polímeros::biopolímeros::proteínas de filamentos intermedios::proteínas de neurofilamentos
COMPUESTOS QUÍMICOS Y DROGAS::factores biológicos::biomarcadores
id ES_1f2fe23f95bdc83e5ef8051641ebe4cd
oai_identifier_str oai:scientiasalut.gencat.cat:11351/11386
network_acronym_str ES
network_name_str España
repository_id_str
dc.title.none.fl_str_mv Temporal Relationship Between Serum Neurofilament Light Chain and Radiologic Disease Activity in Patients With Multiple Sclerosis
title Temporal Relationship Between Serum Neurofilament Light Chain and Radiologic Disease Activity in Patients With Multiple Sclerosis
spellingShingle Temporal Relationship Between Serum Neurofilament Light Chain and Radiologic Disease Activity in Patients With Multiple Sclerosis
Fox, Robert J
Esclerosi múltiple - Imatgeria per ressonància magnètica
Marcadors bioquímics
Filaments citoplasmàtics
DISEASES::Nervous System Diseases::Autoimmune Diseases of the Nervous System::Demyelinating Autoimmune Diseases, CNS::Multiple Sclerosis
Other subheadings::Other subheadings::Other subheadings::/diagnostic imaging
CHEMICALS AND DRUGS::Macromolecular Substances::Polymers::Biopolymers::Intermediate Filament Proteins::Neurofilament Proteins
CHEMICALS AND DRUGS::Biological Factors::Biomarkers
ENFERMEDADES::enfermedades del sistema nervioso::enfermedades autoinmunitarias del sistema nervioso::enfermedades autoinmunes desmielinizantes del SNC::esclerosis múltiple
Otros calificadores::Otros calificadores::Otros calificadores::/diagnóstico por imagen
COMPUESTOS QUÍMICOS Y DROGAS::sustancias macromoleculares::polímeros::biopolímeros::proteínas de filamentos intermedios::proteínas de neurofilamentos
COMPUESTOS QUÍMICOS Y DROGAS::factores biológicos::biomarcadores
title_short Temporal Relationship Between Serum Neurofilament Light Chain and Radiologic Disease Activity in Patients With Multiple Sclerosis
title_full Temporal Relationship Between Serum Neurofilament Light Chain and Radiologic Disease Activity in Patients With Multiple Sclerosis
title_fullStr Temporal Relationship Between Serum Neurofilament Light Chain and Radiologic Disease Activity in Patients With Multiple Sclerosis
title_full_unstemmed Temporal Relationship Between Serum Neurofilament Light Chain and Radiologic Disease Activity in Patients With Multiple Sclerosis
title_sort Temporal Relationship Between Serum Neurofilament Light Chain and Radiologic Disease Activity in Patients With Multiple Sclerosis
dc.creator.none.fl_str_mv Fox, Robert J
Cree, Bruce
de Seze, Jerome
Hartung, Hans-Peter
Jeffery, Douglas
Gold, Ralf
Montalban, Xavier
author Fox, Robert J
author_facet Fox, Robert J
Cree, Bruce
de Seze, Jerome
Hartung, Hans-Peter
Jeffery, Douglas
Gold, Ralf
Montalban, Xavier
author_role author
author2 Cree, Bruce
de Seze, Jerome
Hartung, Hans-Peter
Jeffery, Douglas
Gold, Ralf
Montalban, Xavier
author2_role author
author
author
author
author
author
dc.contributor.none.fl_str_mv Institut Català de la Salut
[Fox RJ] Mellen Center for Multiple Sclerosis, Neurological Institute, Cleveland Clinic, Ohio, United States. [Cree BAC] Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, United States. [de Sèze J] Department of Neurology, Hôpital Civil, Strasbourg, France. [Gold R] Department of Neurology, St. Josef Hospital, Ruhr University, Bochum, Germany. [Hartung HP] Department of Neurology, Heinrich-Heine-University, Düsseldorf, Germany. Brain and Mind Center, University of Sydney, Australia. Department of Neurology, Palacky University Olomouc, Czech Republic. [Jeffery D] Piedmont HealthCare, Mooresville, NC, United States. [Montalban X] Vall d’Hebron Hospital Universitari, Barcelona, Spain
Vall d'Hebron Barcelona Hospital Campus
dc.subject.none.fl_str_mv Esclerosi múltiple - Imatgeria per ressonància magnètica
Marcadors bioquímics
Filaments citoplasmàtics
DISEASES::Nervous System Diseases::Autoimmune Diseases of the Nervous System::Demyelinating Autoimmune Diseases, CNS::Multiple Sclerosis
Other subheadings::Other subheadings::Other subheadings::/diagnostic imaging
CHEMICALS AND DRUGS::Macromolecular Substances::Polymers::Biopolymers::Intermediate Filament Proteins::Neurofilament Proteins
CHEMICALS AND DRUGS::Biological Factors::Biomarkers
ENFERMEDADES::enfermedades del sistema nervioso::enfermedades autoinmunitarias del sistema nervioso::enfermedades autoinmunes desmielinizantes del SNC::esclerosis múltiple
Otros calificadores::Otros calificadores::Otros calificadores::/diagnóstico por imagen
COMPUESTOS QUÍMICOS Y DROGAS::sustancias macromoleculares::polímeros::biopolímeros::proteínas de filamentos intermedios::proteínas de neurofilamentos
COMPUESTOS QUÍMICOS Y DROGAS::factores biológicos::biomarcadores
topic Esclerosi múltiple - Imatgeria per ressonància magnètica
Marcadors bioquímics
Filaments citoplasmàtics
DISEASES::Nervous System Diseases::Autoimmune Diseases of the Nervous System::Demyelinating Autoimmune Diseases, CNS::Multiple Sclerosis
Other subheadings::Other subheadings::Other subheadings::/diagnostic imaging
CHEMICALS AND DRUGS::Macromolecular Substances::Polymers::Biopolymers::Intermediate Filament Proteins::Neurofilament Proteins
CHEMICALS AND DRUGS::Biological Factors::Biomarkers
ENFERMEDADES::enfermedades del sistema nervioso::enfermedades autoinmunitarias del sistema nervioso::enfermedades autoinmunes desmielinizantes del SNC::esclerosis múltiple
Otros calificadores::Otros calificadores::Otros calificadores::/diagnóstico por imagen
COMPUESTOS QUÍMICOS Y DROGAS::sustancias macromoleculares::polímeros::biopolímeros::proteínas de filamentos intermedios::proteínas de neurofilamentos
COMPUESTOS QUÍMICOS Y DROGAS::factores biológicos::biomarcadores
description Serum neurofilament light chain; Radiologic disease; Multiple sclerosis
publishDate 2024
dc.date.none.fl_str_mv 2024
2024
2024
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/11351/11386
url https://hdl.handle.net/11351/11386
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Neurology;102(9)
https://doi.org/10.1212/WNL.0000000000209357
dc.rights.none.fl_str_mv Attribution-NonCommercial-NoDerivatives 4.0 International
http://creativecommons.org/licenses/by-nc-nd/4.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Attribution-NonCommercial-NoDerivatives 4.0 International
http://creativecommons.org/licenses/by-nc-nd/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Wolters Kluwer Health
publisher.none.fl_str_mv Wolters Kluwer Health
dc.source.none.fl_str_mv Scientia
reponame:Scientia. Dipòsit d'Informació Digital del Departament de Salut
instname:Departament de Salut de la Generalitat de Catalunya (DS)
instname_str Departament de Salut de la Generalitat de Catalunya (DS)
reponame_str Scientia. Dipòsit d'Informació Digital del Departament de Salut
collection Scientia. Dipòsit d'Informació Digital del Departament de Salut
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869404385632583680
spelling Temporal Relationship Between Serum Neurofilament Light Chain and Radiologic Disease Activity in Patients With Multiple SclerosisFox, Robert JCree, Brucede Seze, JeromeHartung, Hans-PeterJeffery, DouglasGold, RalfMontalban, XavierEsclerosi múltiple - Imatgeria per ressonància magnèticaMarcadors bioquímicsFilaments citoplasmàticsDISEASES::Nervous System Diseases::Autoimmune Diseases of the Nervous System::Demyelinating Autoimmune Diseases, CNS::Multiple SclerosisOther subheadings::Other subheadings::Other subheadings::/diagnostic imagingCHEMICALS AND DRUGS::Macromolecular Substances::Polymers::Biopolymers::Intermediate Filament Proteins::Neurofilament ProteinsCHEMICALS AND DRUGS::Biological Factors::BiomarkersENFERMEDADES::enfermedades del sistema nervioso::enfermedades autoinmunitarias del sistema nervioso::enfermedades autoinmunes desmielinizantes del SNC::esclerosis múltipleOtros calificadores::Otros calificadores::Otros calificadores::/diagnóstico por imagenCOMPUESTOS QUÍMICOS Y DROGAS::sustancias macromoleculares::polímeros::biopolímeros::proteínas de filamentos intermedios::proteínas de neurofilamentosCOMPUESTOS QUÍMICOS Y DROGAS::factores biológicos::biomarcadoresSerum neurofilament light chain; Radiologic disease; Multiple sclerosisCadena ligera de neurofilamentos séricos; Enfermedad radiológica; Esclerosis múltipleCadena lleugera de neurofilaments sèrics; Malaltia radiològica; Esclerosi múltipleBackground and Objectives Serum neurofilament light chain (sNfL) levels correlate with multiple sclerosis (MS) disease activity, but the dynamics of this correlation are unknown. We evaluated the relationship between sNfL levels and radiologic MS disease activity through monthly assessments during the 24-week natalizumab treatment interruption period in RESTORE (NCT01071083). Methods In the RESTORE trial, participants with relapsing forms of MS who had received natalizumab for ≥12 months were randomized to either continue or stop natalizumab and followed with MRI and blood draws every 4 weeks to week 28 and again at week 52 The sNfL was measured, and its dynamics were correlated with the development of gadolinium-enhancing (Gd+) lesions. Log-linear trend in sNfL levels were modeled longitudinally using generalized estimating equations with robust variance estimator from baseline to week 28. Results Of 175 patients enrolled in RESTORE, 166 had serum samples for analysis. Participants with Gd+ lesions were younger (37.7 vs 43.1, p = 0.001) and had lower Expanded Disability Status Scale scores at baseline (2.7 vs 3.4, p = 0.017) than participants without Gd+ lesions. sNfL levels increased in participants with Gd+ lesions (n = 65) compared with those without (n = 101, mean change from baseline to maximum sNfL value, 12.1 vs 3.2 pg/mL, respectively; p = 0.003). As the number of Gd+ lesions increased, peak median sNfL change also increased by 1.4, 3.0, 4.3, and 19.6 pg/mL in the Gd+ lesion groups of 1 (n = 12), 2–3 (n = 18), 4–9 (n = 21), and ≥10 (n = 14) lesions, respectively. However, 46 of 65 (71%) participants with Gd+ lesions did not increase above the 95th percentile threshold of the group without Gd+ lesions. The initial increase of sNfL typically trailed the first observation of Gd+ lesions, and the peak increase in sNfL was a median [interquartile range] of 8 [0, 12] weeks after the first appearance of the Gd+ lesion. Discussion Although sNfL correlated with the presence of Gd+ lesions, most participants with Gd+ lesions did not have elevations in sNfL levels. These observations have implications for the use and interpretation of sNfL as a biomarker for monitoring MS disease activity in controlled trials and clinical practice.The study was sponsored and funded by Biogen (Cambridge, MA).Wolters Kluwer HealthInstitut Català de la Salut[Fox RJ] Mellen Center for Multiple Sclerosis, Neurological Institute, Cleveland Clinic, Ohio, United States. [Cree BAC] Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, United States. [de Sèze J] Department of Neurology, Hôpital Civil, Strasbourg, France. [Gold R] Department of Neurology, St. Josef Hospital, Ruhr University, Bochum, Germany. [Hartung HP] Department of Neurology, Heinrich-Heine-University, Düsseldorf, Germany. Brain and Mind Center, University of Sydney, Australia. Department of Neurology, Palacky University Olomouc, Czech Republic. [Jeffery D] Piedmont HealthCare, Mooresville, NC, United States. [Montalban X] Vall d’Hebron Hospital Universitari, Barcelona, SpainVall d'Hebron Barcelona Hospital Campus202420242024info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://hdl.handle.net/11351/11386Scientiareponame:Scientia. Dipòsit d'Informació Digital del Departament de Salutinstname:Departament de Salut de la Generalitat de Catalunya (DS)InglésNeurology;102(9)https://doi.org/10.1212/WNL.0000000000209357Attribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccessoai:scientiasalut.gencat.cat:11351/113862026-06-12T09:38:37Z
score 15,812429

Similares en LA Referencia